From CMC strategy and analytics to CDMO partnerships and AI-enabled operations, life sciences ecosystem gathered at Propel Labs to discuss the growing pressure to execute with speed and precision. The biotech industry is entering a new phase where breakthrough science alone is no longer enough to attract capital, reach the clinic, or survive long enough […]
Read More →On June 4th, the BioBuzz community will gather at the Pinkney Innovation Complex for Science and Technology (PIC MC) at Montgomery College — a place that represents far more than buildings and laboratory space. It stands as a lasting example of how education, innovation, and community partnership can come together to create long-term impact. Honoring […]
I am a Senior Quality Compliance Specialist within the CDMO sector of Rose BioSolutions. My primary focus is audit management, inspection, readiness, and risk/change management. Our site in Rockville specializes in the production of adeno-associated virus (AAV), lentivirus, adenovirus, and retrovirus for gene and gene-modified cell therapies. 1) What did you want to be when […]
At our most recent Insights to Impact event in the Philadelphia Region “From Lab to GMP: Building a Clinical Ready Biotech,” industry leaders pulled back the curtain on one of the least glamorous, but most critical, parts of biotech innovation: operational execution. While scientific breakthroughs often dominate headlines, the conversations throughout the evening made one […]
A fireside chat with AstraZeneca’s Dafni Bika at ISPE MAST Showcase made the case that decarbonization, AI, and people-centered leadership are converging into one operating discipline for pharma. When Dafni Bika, Ph.D., started out as a materials scientist and chemical engineer, nobody in her labs said “sustainability.” They called it value engineering — wringing every […]
MANASSAS, Va. —Jeeva Clinical Trials announced the acquisition of Clintelligence AI, an AI-powered protocol intelligence platform designed to improve trial planning, accelerate patient recruitment, and reduce clinical development risk. The acquisition expands Jeeva’s growing AI-ready clinical research infrastructure and strengthens its position as a next-generation platform for decentralized and hybrid clinical trials. The integration of […]
ROCKVILLE, Md. — May 13, 2026 — Bora Pharmaceuticals, a Taiwan-based contract development and manufacturing organization (CDMO), has entered into an agreement to acquire MacroGenics’ biologics manufacturing facility and related warehouse operations in Rockville, Maryland, for $122.5 million upfront, with the potential for an additional $5 million tied to future operational milestones. The transaction expands […]
When Gilead Sciences announced its $7.8 billion acquisition of Arcellx earlier this year, the deal was largely framed as a strategic win in the escalating race to dominate next-generation CAR-T therapies. The acquisition gives Gilead full control of anito-cel, a late-stage multiple myeloma therapy viewed by many as one of the most promising challengers in […]
In life sciences, the conversation around AI has moved quickly from if to how. But beneath that momentum lies a more fundamental question: are organizations actually ready to use it? That gap—between interest and readiness—is becoming one of the defining challenges for the industry. At the upcoming AAPS National Biotechnology Conference, that tension will be […]
For much of modern drug development, the question hasn’t just been can we target the biology—it’s been can we prove it early enough to matter. That tension is becoming increasingly visible as therapies grow more precise and biology more complex. At this year’s AAPS National Biotechnology Conference, that challenge is moving to the forefront, with […]
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
